Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Argus Health
Covington
Farmers Insurance
AstraZeneca
Citi

Generated: June 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIZANIDINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Tizanidine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00047580 Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Sp Completed Elan Pharmaceuticals Phase 3 This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.
NCT00178646 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed Allergan Phase 4 The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.
NCT00178646 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed The University of Texas Health Science Center, Houston Phase 4 The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.
NCT00228267 Propofol Injection for Daily Headache Completed University of Alberta Phase 2 Hypothesis A single subanesthetic dose of propofol will result in improved pain and quality of life for the next 30 days in persons with chronic daily headache (CDH) Specific objectives To measure the effect of a single infusion of propofol at 40 mcg / kg / minute over 60 mins on headache-related quality of life (measured by the Headache Disability Index) and on headache severity (measured by the Headache Index) in subjects with chronic daily headache over 30 days45-47
NCT00287157 Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI) Completed Teva GTC Phase 1 Nightly administration of a unique, sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve sleep and next-day functioning in CP (cerebral palsy) patients. It is hypothesized that this improvement in sleep efficiency (i.e.,fewer wake episodes, longer time asleep, etc.) with resulting improvement in quality-of-life (i.e.,improvements in next-day functioning, cognition and movement) may also be seen in a similar patient population, i.e., children with traumatic brain injury (TBI).
NCT00358293 Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity Completed Teva GTC Phase 1/Phase 2 Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following dosing in 20 multiple sclerosis (MS) patients. This improvement was statistically significant when compared to oral tizanidine dosing. The current study is being undertaken to see if increasing the dose to 12 mg once nightly will result in an even greater improvement, with a longer effect, i.e., next day improvement in spasticity both in the morning as well as in the late afternoon.
NCT00464958 One Year Extension Study To Protocol C2/5/TZ:MS-05 Terminated Teva GTC Phase 1/Phase 2 Open label, one year extension study to evaluate the clinical efficacy and safety of 12 mg sublingual tizanidine administered once nightly in MS patients who successfully completed Phase I/II protocol C2/5/TZ:MS-05 at the Tel Aviv Sourasky Medical Center, Department of Neurology, Dr. Arnon Karni, PI.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tizanidine Hydrochloride

Condition Name

Condition Name for Tizanidine Hydrochloride
Intervention Trials
Spasticity 3
Multiple Sclerosis 3
Spinal Cord Injury 2
Muscle Spasticity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tizanidine Hydrochloride
Intervention Trials
Muscle Spasticity 6
Multiple Sclerosis 4
Low Back Pain 2
Back Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tizanidine Hydrochloride

Trials by Country

Trials by Country for Tizanidine Hydrochloride
Location Trials
United States 27
Canada 4
Israel 3
Korea, Republic of 3
Turkey 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tizanidine Hydrochloride
Location Trials
Texas 3
California 3
Illinois 2
Florida 2
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tizanidine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Tizanidine Hydrochloride
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2 2
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tizanidine Hydrochloride
Clinical Trial Phase Trials
Completed 15
Terminated 2
Enrolling by invitation 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tizanidine Hydrochloride

Sponsor Name

Sponsor Name for Tizanidine Hydrochloride
Sponsor Trials
Teva GTC 3
Dr. Reddy's Laboratories Limited 2
Acorda Therapeutics 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tizanidine Hydrochloride
Sponsor Trials
Industry 13
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
Argus Health
Deloitte
Accenture
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.